NAMS Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

2.85M

-77.67%

-0.407

-57.13%

0.00

-100%

-0.448

+32.24%

0.00

-100%

-0.462

+207.51%

Estimates Revision

The market is revising Downward the revenue expectations for NewAmsterdam Pharma Company N.V. (NAMS) for FY2025, with the revenue forecasts being adjusted by -13.12% over the past three months. During the same period, the stock price has changed by -7.23%.

Revenue Estimates for FY2025

Revise Downward

-13.12%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+13.37%

In Past 3 Month

Stock Price

Go Down

-7.23%

In Past 3 Month

10 Analyst Rating

Wall Street analysts forecast NAMS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NAMS is 46.38 USD with a low forecast of 30.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

30.00

Averages

46.38

High

60.00

Current: 0.000

Low

30.00

Averages

46.38

High

60.00

H.C. Wainwright

Joseph Pantginis

initiated

$52

2025-10-20

Reason

H.C. Wainwright

Joseph Pantginis

Price Target

$52

2025-10-20

initiated

Reason

H.C. Wainwright analyst Joseph Pantginis assumed coverage of NewAmsterdam Pharma with a Buy rating and $52 price target. NewAmsterdam is a late clinical-stage biopharmaceutical company developing obicetrapib, a non-statin, next-generation cholesterol ester transfer protein small molecule inhibitor for low-density lipoprotein cholesterol reduction, the analyst tells investors in a research note. The firm says obicetrapib is :poised to burst into the lipid-lowering space."

Citi

Buy

upgrade

$42 -> $50

2025-10-17

Reason

Citi

Price Target

$42 -> $50

2025-10-17

upgrade

Buy

Reason

Citi raised the firm's price target on NewAmsterdam Pharma to $50 from $42 and keeps a Buy rating on the shares as part of a Q3 preview for the biotechnology group. The firm believes investor interest in the smaller cap biotech names is building, which could set the group up well for 2026.

Wells Fargo

Overweight

initiated

$45

2025-08-25

Reason

Wells Fargo

Price Target

$45

2025-08-25

initiated

Overweight

Reason

Wells Fargo initiated coverage of NewAmsterdam Pharma with an Overweight rating and $45 price target. The firm believes cholesteryl ester transfer protein inhibition represents an \"exciting new frontier\" for lipid lowering and a multibillion dollar opportunity. NewAmsterdam has built obicetrapib on the foundations of four prior CETP inhibitors in the industry and the ongoing PREVAIL study is set up for success, the analyst tells investors in a research note.

Goldman Sachs

Neutral

initiated

$27

2025-07-17

Reason

Goldman Sachs

Price Target

$27

2025-07-17

initiated

Neutral

Reason

Goldman Sachs initiated coverage of NewAmsterdam Pharma with a Neutral rating and $27 price target. The firm sees the stock as range-bound with results from the Phase 3 PREVAIL cardiovascular outcomes trial for the company's lead candidate obicetrapib is not expected until late 2026. However, Goldman is "constructive" on obicetrapib's LDL-C lowering and other lipid effects.

Citi

initiated

$42

2025-06-18

Reason

Citi

Price Target

$42

2025-06-18

initiated

Reason

Citi initiated coverage of NewAmsterdam Pharma with a Buy rating and $42 price target. The LDL cholesterol lowering market is "large and with substantial remaining unmet need," the analyst tells investors in a research note. The firm says upwards of 75% of patients with atherosclerotic cardiovascular disease still need additional therapies to help reach their targeted LDL-C goal level, and the growth of the non-statin market has seen high double digit precent growth year-over-year since 2020. NewAmsterdam's obicetrapib aims to be a first-in-class agent that would be an add-on to patients on statins to help address LDL-C levels, and with potential to be used in combination therapy with ezetimibe for those who need additional lipid lowering, contends Citi.

Stifel

initiated

$44

2025-06-09

Reason

Stifel

Price Target

$44

2025-06-09

initiated

Reason

Stifel initiated coverage of NewAmsterdam Pharma with a Buy rating and $44 price target. NewAmsterdam sets up as "a unique, late-stage cardiovascular-focused company" with a near-term path to regulatory filings and a cardiovascular outcomes trial that "very likely differentiates obicetrapib" within the large, growing lipid-lowering market, the analyst tells investors. There is "a significant amount of data/literature" supporting that obicetrapib and the PREVAIL trial are "fundamentally different" and even with "conservative commercial assumptions per docs," the firm sees the potential for significant upside to shares.

Valuation Metrics

The current forward P/E ratio for NewAmsterdam Pharma Company NV (NAMS.O) is -19.47, compared to its 5-year average forward P/E of 1.14. For a more detailed relative valuation and DCF analysis to assess NewAmsterdam Pharma Company NV 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

1.14

Current PE

-19.47

Overvalued PE

32.44

Undervalued PE

-30.17

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

1.33

Current EV/EBITDA

-17.53

Overvalued EV/EBITDA

10.40

Undervalued EV/EBITDA

-7.75

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

254.33

Current PS

1373.80

Overvalued PS

633.24

Undervalued PS

-124.59

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

NAMS News & Events

Events Timeline

No data

News

2.0

01-09Newsfilter

NewAmsterdam Pharma Expects EMA Approval for Obicetrapib in 2H26

5.0

2025-12-05Globenewswire

NewAmsterdam Grants 40,000 Share Options to Attract New Hires

4.0

2025-10-20Benzinga

HC Wainwright & Co. Initiates Coverage on NewAmsterdam Pharma Co with a Buy Rating and Sets Price Target at $52

People Also Watch

Frequently Asked Questions

What is NewAmsterdam Pharma Company NV (NAMS) stock price today?

The current price of NAMS is 34.37 USD — it has decreased -3.99 % in the last trading day.

What is NewAmsterdam Pharma Company NV (NAMS)'s business?

NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.

What is the price predicton of NAMS Stock?

What is NewAmsterdam Pharma Company NV (NAMS)'s revenue for the last quarter?

NewAmsterdam Pharma Company NV revenue for the last quarter amounts to 348.00K USD, decreased -98.80 % YoY.

What is NewAmsterdam Pharma Company NV (NAMS)'s earnings per share (EPS) for the last quarter?

NewAmsterdam Pharma Company NV. EPS for the last quarter amounts to -0.61 USD, increased 238.89 % YoY.

What changes have occurred in the market's expectations for NewAmsterdam Pharma Company NV (NAMS)'s fundamentals?

How many employees does NewAmsterdam Pharma Company NV (NAMS). have?

NewAmsterdam Pharma Company NV (NAMS) has 68 emplpoyees as of January 10 2026.

What is NewAmsterdam Pharma Company NV (NAMS) market cap?

Today NAMS has the market capitalization of 3.90B USD.